Searching US Patent Collection...

	PAT. NO.		Title
1	11,021,707		Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
2	11,008,570		3' end caps for RNAi agents for use in RNA interference
3	11,001,845		Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
4	10,968,449		Compositions and methods for controlling Leptinotarsa
5	10,947,541		Treatment of atopic dermatitis and asthma using RNA complexes that target IL4R.alpha., TRPA1, or F2RL1
6	10,934,550		Immunotherapy of cancer
7	10,927,376		Compositions of asymmetric interfering RNA and uses thereof
8	10,913,948		RNA interference in dermal and fibrotic indications
9	10,900,039		Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
10	10,900,038		siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof
11	10,889,815		RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
12	10,888,579		Compositions for conferring tolerance to viral disease in social insects, and the use thereof
13	10,881,743		Compositions and methods of treating muscle atrophy and myotonic dystrophy
14	10,876,121		EGFR nucleic acids and uses thereof
15	10,876,119		Reduced size self-delivering RNAI compounds
16	10,858,656		KRAS nucleic acids and uses thereof
17	10,844,385		Beta-catenin nucleic acids and uses thereof
18	10,829,761		Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
19	10,829,760		Nucleic acid molecules inducing RNA interference, and uses thereof
20	10,815,485		RNA interference in skin indications
21	10,808,247		Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
22	10,801,028		Compositions for controlling Varroa mites in bees
23	10,800,848		Nucleic acid-polypeptide compositions and uses thereof
24	10,787,519		Nucleic acid-polypeptide compositions and uses thereof
25	10,774,332		Interfering RNA molecules
26	10,774,330		Reduced size self-delivering RNAI compounds
27	10,736,848		Vaccine nanotechnology
28	10,731,157		Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
29	10,731,155		In vivo production of small interfering RNAs that mediate gene silencing
30	10,683,500		UNA oligomers having reduced off-target effects in gene silencing
31	10,662,430		RNA interference in ocular indications
32	10,662,428		RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
33	10,655,184		Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease
34	10,633,656		RNA interference mediating small RNA molecules
35	10,633,654		Modified RNAi polynucleotides and uses thereof
36	10,626,398		Oligonucleotide compositions with enhanced efficiency
37	10,604,758		Therapeutic oligomers for treating amyloidosis
38	10,604,574		Oncolytic viral delivery of therapeutic polypeptides
39	10,597,676		Compositions and methods for controlling Leptinotarsa
40	10,590,423		Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3
41	10,584,335		Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
42	10,550,188		Nucleic acid-polypeptide compositions and uses thereof
43	10,519,449		Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
44	10,519,447		Therapeutic UNA oligomers and uses thereof
45	10,519,446		Organic compounds to treat hepatitis B virus
46	10,508,277		Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
47	10,494,631		siRNA compounds comprising terminal substitutions
48	10,487,149		Nucleic acid-polypeptide compositions and uses thereof
49	10,479,992		RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
50	10,472,625		RNA sequence-specific mediators of RNA interference